Strategic acquisitions MLS has a history of strategic acquisitions, including PLUS Diagnostics in 2019 and PLUS Diagnostics acquisition news in 2025, indicating growth through expanded pathology offerings and capabilities that can open cross-sell opportunities for complementary lab and IT services.

Integrated health IT Beyond pathology services, the company provides health IT consulting focused on MIPS, quality reporting, Meaningful Use, security risk assessments, and HIPAA compliance—a solid basis for offering expanded analytics, compliance tooling, and practice optimization services to current and prospective clients.

Regional scale With 51-200 employees and revenue in the low hundreds of millions, MLS operates at a scale that supports national or multi-region coverage for enterprise-grade laboratory services, enabling sales plays around scalable deployment, contracting, and managed services for large practices and health systems.

Clinical partnerships Past and ongoing collaborations with Janssen Biotech and Biocept demonstrate MLS’s active partnerships in therapeutic monitoring and oncology testing, suggesting opportunities to cross-sell advanced companion diagnostics, liquid biopsy services, or pharmacogenomics programs to oncology groups.

Competitive positioning Positioned as a leading expert in anatomic pathology with a tech-forward approach and academic rigor, MLS presents as a quality-driven partner for large multisite practices seeking reliable pathology services, and a doorway to expanding into managed pathology networks and IT-enabled care coordination.